Summary
Profound Medical Q2 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product shipments completed in July rather than June.
Profound Medical (PROF) Q2 Earnings Surpass Estimates
Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.52 per share a year ago.
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 298,358 | $1.47M | $2.21M | $739,772.1 | 50.29% |
 W. Travis McKinney HB Wealth Management LLC | 30,000 | $194,400 | $221,400 | $27,000 | 13.89% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 66 | $427.63 | $487.08 | $59.45 | 13.9% |
 Jay Annis Annis Gardner Whiting Capital Advisors, LLC | 40,000 | $259,200 | $293,600 | $34,400 | 13.27% |
 Kevin Bresler TD Waterhouse Canada Inc. | 138,110 | $867,997.75 | $1.02M | $151,254.05 | 17.43% |
Profound Medical Corp. (PROF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Profound Medical Corp. ever had a stock split?
Profound Medical Corp. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Arun Swarup Menawat CEO | NASDAQ (CM) Exchange | 74319B502 CUSIP |
| CA Country | 162 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Profound Medical Corp. is a commercial-stage medical device company that focuses on developing magnetic resonance guided ablation procedures. These revolutionary procedures are designed for treating various conditions such as prostate disease, uterine fibroids, and providing palliative pain treatment. The company has a global presence with operations in Canada, Germany, the United States, and Finland. With its headquarters located in Mississauga, Canada, Profound Medical Corp. leverages state-of-the-art technology to improve patient care in hospitals and treatment facilities worldwide.
Products and Services
- TULSA-PRO System: This innovative system works seamlessly with magnetic resonance imaging (MRI) scanners to provide a highly precise treatment option for prostate disease. It is designed to deliver targeted therapy with minimal invasiveness, aiming to reduce side effects and improve recovery times for patients. The TULSA-PRO system underscores Profound Medical Corp.’s commitment to advancing prostate disease treatment through technology.
- Sonalleve: Sonalleve is a versatile therapeutic platform that offers non-invasive treatment solutions for uterine fibroids and palliative pain relief for patients suffering from bone metastases. The technology behind Sonalleve uses high-intensity focused ultrasound (HIFU) to target and treat the affected areas without the need for surgical intervention. This platform demonstrates the company’s dedication to providing innovative and patient-centric treatments for complex health issues.
